A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

PHASE1UnknownINTERVENTIONAL

Enrollment

105

Participants

Timeline

Start Date

December 2, 2022

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2023

Conditions

HIV Infections

Interventions

DRUG

VH4524184

VH4524184 will be administered.

DRUG

Midazolam

Midazolam will be administered in the highest dose cohort in Part 2 (Cohorts 8 or 9).

DRUG

Placebo

Placebo will be administered.

Trial Locations (1)

RECRUITING

GSK Investigational Site, Baltimore